Research ArticleCORONAVIRUS

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19

See allHide authors and affiliations

Science Immunology  10 Mar 2021:
Vol. 6, Issue 57, eabg9873
DOI: 10.1126/sciimmunol.abg9873

GM-CSF is a targetable marker of COVID-19 severity

Critical respiratory failure in COVID-19 is an inflammatory disease—several proinflammatory factors correlate with disease severity in COVID-19, and anti-inflammatory treatments such as corticosteroids and anti–IL-6 monoclonal antibodies can reduce mortality. There is a need to identify additional “targetable” proinflammatory factors that correlate with disease severity. Here, Thwaites et al. analyzed the plasma of 471 hospitalized COVID-19 patients, finding that IL-6 and GM-CSF were substantially elevated in those with severe disease. GM-CSF was elevated in cases of fatal COVID-19, but not in fatal influenza, whereas IL-6 was elevated in both. Thus, elevated GM-CSF distinguishes severe COVID-19 from severe influenza, providing insights into disease pathogenesis and a theoretical rationale for therapeutic inhibition of GM-CSF in COVID-19. Inhibitor studies are now ongoing in COVID-19.

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

View Full Text

Stay Connected to Science Immunology